HitGen 将来の成長

Future 基準チェック /36

HitGen利益と収益がそれぞれ年間20.3%と19.4%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に5.1% 22.3%なると予測されています。

主要情報

20.3%

収益成長率

22.3%

EPS成長率

Life Sciences 収益成長	31.9%
収益成長率	19.4%
将来の株主資本利益率	5.1%
アナリストカバレッジ	Low
最終更新日	05 Nov 2024

今後の成長に関する最新情報

Recent updates

Optimistic Investors Push HitGen Inc. (SHSE:688222) Shares Up 51% But Growth Is Lacking

Oct 08

HitGen Inc. (SHSE:688222) Shares Could Be 26% Above Their Intrinsic Value Estimate

Jul 03

HitGen (SHSE:688222) Seems To Use Debt Rather Sparingly

Jun 06

HitGen Inc.'s (SHSE:688222) 28% Jump Shows Its Popularity With Investors

Mar 07

業績と収益の成長予測

SHSE:688222 - アナリストの将来予測と過去の財務データ ( )CNY Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	645	80	30	100	3
12/31/2025	523	62	3	67	3
12/31/2024	440	50	-4	59	3
9/30/2024	424	53	101	158	N/A
6/30/2024	410	45	111	170	N/A
3/31/2024	409	64	103	146	N/A
12/31/2023	371	41	71	125	N/A
9/30/2023	357	33	15	125	N/A
6/30/2023	347	38	-6	96	N/A
3/31/2023	327	23	-31	78	N/A
12/31/2022	330	25	-35	53	N/A
9/30/2022	302	44	-120	12	N/A
6/30/2022	296	36	-126	15	N/A
3/31/2022	314	51	-110	24	N/A
12/31/2021	311	63	-96	43	N/A
9/30/2021	345	79	14	67	N/A
6/30/2021	311	69	-28	43	N/A
3/31/2021	269	61	-72	18	N/A
12/31/2020	244	64	-81	2	N/A
9/30/2020	235	61	-85	-16	N/A
6/30/2020	244	76	27	73	N/A
3/31/2020	258	85	85	121	N/A
12/31/2019	264	120	107	168	N/A
12/31/2018	151	45	-23	51	N/A
12/31/2017	53	-23	N/A	-2	N/A

アナリストによる今後の成長予測

収入対貯蓄率: 688222の予測収益成長率 (年間20.3% ) は貯蓄率 ( 2.8% ) を上回っています。

収益対市場: 688222の収益 ( 20.3% ) CN市場 ( 26.3% ) よりも低い成長が予測されています。

高成長収益: 688222の収益は今後 3 年間で大幅に増加すると予想されています。

収益対市場: 688222の収益 ( 19.4% ) CN市場 ( 13.9% ) よりも速いペースで成長すると予測されています。

高い収益成長: 688222の収益 ( 19.4% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: 688222の自己資本利益率は、3年後には低くなると予測されています ( 5.1 %)。

HitGen 将来の成長

Future 基準チェック /36

主要情報

今後の成長に関する最新情報

Price target increased by 43% to CN¥16.90

Consensus EPS estimates fall by 41%

Price target increased by 22% to CN¥23.00

Consensus revenue estimates fall by 17%

Price target increased to CN¥18.90

Price target decreased to CN¥28.50

Recent updates

New minor risk - Share price stability

Price target increased by 43% to CN¥16.90

Third quarter 2024 earnings released: EPS: CN¥0.18 (vs CN¥0.031 in 3Q 2023)

Now 23% overvalued after recent price rise

Optimistic Investors Push HitGen Inc. (SHSE:688222) Shares Up 51% But Growth Is Lacking

New minor risk - Share price stability

HitGen Inc. to Report Q3, 2024 Results on Oct 26, 2024

Now 20% overvalued

Now 25% overvalued

HitGen Inc. (SHSE:688222) Shares Could Be 26% Above Their Intrinsic Value Estimate

HitGen Inc. to Report First Half, 2024 Results on Aug 29, 2024

HitGen (SHSE:688222) Seems To Use Debt Rather Sparingly

HitGen Inc., Annual General Meeting, May 22, 2024

First quarter 2024 earnings released: EPS: CN¥0.03 (vs CN¥0.02 loss in 1Q 2023)

HitGen Inc. to Report Q1, 2024 Results on Apr 25, 2024

Now 23% undervalued

HitGen Inc.'s (SHSE:688222) 28% Jump Shows Its Popularity With Investors

Full year 2023 earnings: EPS exceeds analyst expectations

Third quarter 2023 earnings released

New minor risk - Share price stability

Consensus EPS estimates fall by 41%

Second quarter 2023 earnings released: EPS: CN¥0.022 (vs CN¥0 in 2Q 2022)

HitGen Inc. to Report Q2, 2023 Results on Aug 23, 2023

HitGen Inc. Launches A Newly Upgraded Version of OpenDEL™, A Self-Service Screening Kit, to Facilitate Innovative Drug Discovery Research

Price target increased by 22% to CN¥23.00

First quarter 2023 earnings released: CN¥0.02 loss per share (vs CN¥0.02 loss in 1Q 2022)

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates fall by 17%

Price target increased to CN¥18.90

Third quarter 2022 earnings released: EPS: CN¥0.052 (vs CN¥0.02 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0 (vs CN¥0.06 in 2Q 2021)

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to CN¥28.50

Full year 2021 earnings: EPS and revenues miss analyst expectations

Second quarter 2021 earnings released: EPS CN¥0.06 (vs CN¥0.02 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.01 (vs CN¥0.02 in 1Q 2020)

Cocrystal Pharma, Inc. Extends Drug Discovery Collaboration with HitGen and InterX, Inc

Full year 2020 earnings released: EPS CN¥0.17 (vs CN¥0.33 in FY 2019)

Revenue behind estimates

HitGen and UPPTHERA Entera Into Drug Discovery Research Collaboration

New 90-day high: CN¥40.13

New 90-day low: CN¥29.19

HitGen Announces License Agreement With Merck & Co., Inc., Kenilworth, NJ USA to Access Compounds for Potential Development of Novel Class of Drugs

Cedilla Therapeutics, Inc. and HitGen Inc. Announces Research Collaboration Focused on Dna-Encoded Library Based Drug Discovery

HitGen Licenses its Trk/ROS1 Inhibitor HG030 to Baiyunshan for Development and Commercialisation in China

New 90-day low: CN¥31.33

HitGen Inc. to Report Q3, 2020 Results on Oct 31, 2020

New 90-day low: CN¥36.33

HitGen Inc. (SHSE:688222) agreed to acquire Vernalis (R&D) Limited from Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND) for $25 million.

New 90-day low: CN¥37.61

New 90-day low - CN¥38.20

First half earnings released

New 90-day low - CN¥40.30

HitGen Inc. to Report First Half, 2020 Results on Aug 21, 2020

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘